Trial Profile
Phase III Clinical Trial of TO-194SL - Efficacy and Safety Evaluation in Patients with Japanese Cedar Pollinosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Japanese cedar pollen allergy immunotherapy Torii Pharmaceutical (Primary)
- Indications Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Torii Pharmaceutical
- 10 Nov 2014 New trial record
- 14 Sep 2012 According to a Torii Pharmaceutical media release, the company will conduct the full analysis of the study results and plans to submit a New Drug Application in Japan in March 2013.